| FACTOR | Effect on Aldosterone plasma concentration | Effect on Renin plasma concentration | Effect on Aldosterone-Renin Ratio (ARR) |
|--|--|--------------------------------------|--|
| MEDICATIONS | | | |
| β-Adrenergic blockers | Decrease | Decrease | False Positive |
| Central agonists (clonidine, α-methyldopa) | Decrease | Decrease | False Positive |
| NSAIDs | Decrease | Decrease | False Positive |
| K ⁺ -wasting diuretics | No effect / Increase | Increase | False Negative |
| K ⁺ -sparing diuretics | Increase | Increase | False Negative |
| ACE inhibitors | Decrease | Increase | False Negative |
| ARBs | Decrease | Increase | False Negative |
| Ca ²⁺ blockers (DHPs) | No effect / Decrease | Increase | False Negative |
| Renin inhibitors | Decrease | Increase | False Negative |
| POTASSIUM STATUS | | | |
| Hypokalaemia | Decrease | No effect / Increase | False Negative |
| DIETARY SODIUM | | | |
| Sodium restriction | Increase | Increase | False Negative |
| Sodium loading | Decrease | Decrease | False Positive |
| OTHER CONDITIONS | | | |
| Advancing age | Decrease | Decrease | False Positive |
| Premenopausal women (vs. males) ^a | No effect / Increase | Decrease | False Positive |
| Renal impairment | No effect | Decrease | False Positive |
| PHA-2 (pseudohypoaldosteronism type 2) | No effect | Decrease | False Positive |
| Pregnancy | Increase | Increase | False Negative |
| Renovascular hypertension | Increase | Increase | False Negative |
| Malignant hypertension | Increase | Increase | False Negative |

^a In premenopausal, ovulating women, plasma aldosterone levels measured during menses or proliferative phase are similar to those of men but rise briskly in the luteal phase. Because renin levels are lower, ARR is higher in women compared to men for all phases of the cycle, but especially during the luteal phase.

Table source: Funder et al. (2016) 'The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline', J Clin Endocrinol Metab, 101(5), pp. 1889-916